- Home
- LBRX vs PRME Comparison
LBRX vs PRME Comparison
Compare LBRX & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LBRX | PRME |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 563.2M | 666.1M |
| IPO Year | 2025 | 2022 |
Fundamental Metrics
Financial Performance| Metric | LBRX | PRME |
|---|---|---|
| Price | $22.65 | $4.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $49.00 | $6.42 |
| AVG Volume (30 Days) | 239.5K | ★ 3.3M |
| Earning Date | 02-15-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,977,000.00 |
| Revenue This Year | N/A | $95.64 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 647.13 |
| 52 Week Low | $13.36 | $1.11 |
| 52 Week High | $24.46 | $6.94 |
Technical Indicators
Market Signals| Indicator | LBRX | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 52.48 | 50.62 |
| Support Level | $21.82 | $4.08 |
| Resistance Level | $24.46 | $4.56 |
| Average True Range (ATR) | 1.84 | 0.35 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 53.25 | 33.40 |
Price Performance
Historical ComparisonAbout LBRX LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.